Table 2.
HCVAD + ponatinib vs. HCVAD + dasatinib | HR | 95% CI | P |
---|---|---|---|
Negative MRD on D21 by FCM | 0.516 | 0.281-0.947 | 0.03 |
Complete cytogenetic response at CR | 0.238 | 0.078-0.722 | 0.01 |
Molecular response at CR | |||
CMR | 0.634 | 0.278-1.449 | 0.28 |
MMR or deeper | 0.409 | 0.175-0.954 | 0.04 |
Molecular response at 3 months | |||
CMR | 0.352 | 0.137-0.904 | 0.03 |
MMR or deeper | 0.195 | 0.044-0.854 | 0.03 |
Survival outcomes | |||
EFS | 0.486 | 0.303-0.778 | 0.003 |
OS | 0.374 | 0.208-0.673 | 0.001 |
Abbreviations: HCVAD, hyper-CVAD; HR hazard ratio; CI, confidence interval; MRD, minimal residual disease; FCM, flow cytometry; D21, day 21 of induction therapy; CR, complete response; CMR, complete molecular response; MMR, major molecular response; EFS, event-free survival; OS, overall survival.